Long-Term Evolution of Disease Behavior of Crohn's Disease

Cosnes, Jacques; Cattan, Stéphane; Blain, Antoine; Beaugerie, Laurent; Carbonnel, Franck; Parc, R; Gendre, Jean–Pierre

doi:10.1097/00054725-200207000-00002

Cited by 1,226 publications

(795 citation statements)

References 20 publications

Supporting

Mentioning

739

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, one-third of infliximab-experienced patients had stricturing disease, which is in accordance with their longer disease duration (10 years). 18 As expected, a greater proportion of infliximab-experienced patients had a history of corticosteroid and immunosuppressant use than infliximab-naïve patients, most likely because, at the time of recruitment, infliximab was approved as thirdline therapy and concomitant immunosuppression 19 was also indicated to minimize the development of antiinfliximab antibodies. 8 Similar findings for prior infliximab exposure have been reported in phase 3 trials of adalimumab.…”

Section: Discussionmentioning

confidence: 67%

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

Hanauer

Panés

Colombel

et al. 2010

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 67%

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

Hanauer

Panés

Colombel

et al. 2010

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Crohn's disease (CD) is a chronic transmural intestinal inflammatory disease characterized by episodes of inflammation alternating with periods of remission [1]. CD can be localized to any part of the gastrointestinal tract, although ileal and colonic involvement is most frequent.…”

Section: Introductionmentioning

confidence: 99%

SICUS and CEUS imaging in Crohn’s disease: an update

et al. 2017

View full text Add to dashboard Cite

Endoscopy remains the main technique in the diagnosis and treatment of Crohn's disease (CD); nevertheless, the recent development of innovative and non-invasive imaging techniques has led to a new tool in the exploration of small bowel in CD patients. This paper reviews the available data on ultrasound imaging used for the evaluation of CD, highlighting the role of small intestine contrast-enhanced ultrasonography with the use of oral and intravenous contrast agents.Keywords Crohn's disease Á Contrast-enhanced ultrasound Á Small intestine contrast ultrasonography Sommario Nell'iter diagnostico e terapeutico della malattia di Crohn l'endoscopia rappresenta la principale metodica strumentale. Tuttavia, la recente introduzione di tecniche di imaging innovative e non invasive ha implementato lo studio dell'intestino nelle malattie infiammatorie croniche intestinali. La seguente revisione raccoglie i dati disponibili in letteratura relativi all'utilizzo dell'ecografia con mezzo di contrasto, sia orale (SICUS) sia endovenoso (CEUS), nella valutazione dei pazienti affetti da malattia di Crohn.

show abstract

“…Patients who initially present with inflammatory disease may eventually develop complications involving strictures or perforation [7]. The extent of UC may also progress over time [8,9].…”

Section: Introductionmentioning

confidence: 99%

Emerging biologics in inflammatory bowel disease

Chan

2016

J Gastroenterol

View full text Add to dashboard Cite

Early biologic therapy is recommended in patients with inflammatory bowel disease and poor prognostic factors and in those refractory to conventional medications. Anti-tumor necrosis factor (anti-TNF) agents are the most commonly used biologic agents. However, some patients may not have an initial response to anti-TNF therapy, and one-third will develop loss of response over time. Anti-TNF drugs can also be associated with side effects. In addition, the use of biologics is currently limited by their cost, especially in developing countries. A number of new therapeutic targets, including novel small molecules, and cellular therapy are available or under investigation. These novel molecules include oral Janus kinase (JAK) inhibitor (tofacitinib), interleukin inhibitor (ustekinumab), oral SMAD7 antisense oligonucleotide (mongersen), and anti-integrin inhibitors (vedolizumab). Here, we review the mechanisms of action, the efficacy, and the safety data of these novel agents. Biological products that are highly similar to reference biologic products whose patents have expired-also known as ''biosimilars''-can be produced at lower cost with similar efficacy, and are also available for the treatment of IBD. We review the efficacy data for such agents as well.

show abstract

Long-Term Evolution of Disease Behavior of Crohn's Disease

Abstract: Most patients with CD will eventually one day develop a stricturing or a perforating complication. Initial location determines the type of the complication. Classification of patients into a behavioral group from previous history has no impact upon activity during the following years.

Cited by 1,226 publications

References 20 publications

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

SICUS and CEUS imaging in Crohn’s disease: an update

Emerging biologics in inflammatory bowel disease

Contact Info

Product

Resources

About